| __timestamp | Mesoblast Limited | Pfizer Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 25434000 | 9577000000 |
| Thursday, January 1, 2015 | 23783000 | 9648000000 |
| Friday, January 1, 2016 | 29763000 | 12329000000 |
| Sunday, January 1, 2017 | 12065000 | 11240000000 |
| Monday, January 1, 2018 | 5508000 | 11248000000 |
| Tuesday, January 1, 2019 | 75173000 | 10219000000 |
| Wednesday, January 1, 2020 | 81497000 | 8692000000 |
| Friday, January 1, 2021 | 85731000 | 30821000000 |
| Saturday, January 1, 2022 | 63572000 | 34344000000 |
| Sunday, January 1, 2023 | 54922000 | 29687000000 |
| Monday, January 1, 2024 | 41070000 | 17851000000 |
In the ever-evolving pharmaceutical industry, understanding cost dynamics is crucial. From 2014 to 2023, Pfizer Inc. and Mesoblast Limited have shown contrasting trends in their cost of revenue. Pfizer, a global giant, consistently reported costs in the billions, peaking in 2022 with a 20% increase from 2021. This surge reflects its expansive operations and market reach. In contrast, Mesoblast, a smaller biotech firm, experienced a more volatile trajectory. Its costs spiked in 2019, marking a 1,265% increase from 2018, before stabilizing in subsequent years. Notably, 2023 data for Pfizer is missing, hinting at potential reporting delays or strategic shifts. This analysis underscores the diverse financial landscapes within the pharmaceutical sector, where scale and strategy significantly influence cost structures.
Analyzing Cost of Revenue: Pfizer Inc. and Sanofi
Cost of Revenue Trends: Pfizer Inc. vs BeiGene, Ltd.
Analyzing Cost of Revenue: Pfizer Inc. and Biogen Inc.
Cost of Revenue Comparison: Pfizer Inc. vs Cytokinetics, Incorporated
Cost Insights: Breaking Down Pfizer Inc. and Taro Pharmaceutical Industries Ltd.'s Expenses
Comparing Cost of Revenue Efficiency: Takeda Pharmaceutical Company Limited vs Mesoblast Limited
Cost Insights: Breaking Down Biogen Inc. and Mesoblast Limited's Expenses
Cost of Revenue: Key Insights for Neurocrine Biosciences, Inc. and Mesoblast Limited
Analyzing Cost of Revenue: Walgreens Boots Alliance, Inc. and Mesoblast Limited
Cost of Revenue Comparison: ADMA Biologics, Inc. vs Mesoblast Limited
Comparing Cost of Revenue Efficiency: Mesoblast Limited vs Iovance Biotherapeutics, Inc.
Comparing Cost of Revenue Efficiency: Mesoblast Limited vs Amphastar Pharmaceuticals, Inc.